keyword
MENU ▼
Read by QxMD icon Read
search

Onabotulinumtoxina

keyword
https://www.readbyqxmd.com/read/28213829/onabotulinumtoxina-effectiveness-on-chronic-migraine-negative-emotional-states-and-sleep-quality-a-single-center-prospective-cohort-study
#1
Elif Ilgaz Aydinlar, Pinar Yalinay Dikmen, Seda Kosak, Ayse Sagduyu Kocaman
BACKGROUND: OnabotulinumtoxinA (OnabotA) is considered effective in in patients with chronic migraine (CM) who failed on traditional therapies. This study was designed to evaluate the effect of OnabotA injection series on migraine outcome, negative emotional states and sleep quality in patients with CM. METHODS: A total of 190 patients with CM (mean (SD) age: 39.3 (10.2) years; 87.9% were female) were included. Data on Pittsburgh sleep quality index (PSQI), headache frequency and severity, number of analgesics used, Migraine Disability Assessment Scale...
December 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28202358/a-prospective-multicenter-double-blind-randomized-trial-of-bladder-instillation-of-liposome-formulation-onabotulinumtoxina-for-interstitial-cystitis-bladder-pain-syndrome
#2
Yao-Chi Chuang, Hann-Chorng Kuo
BACKGROUND: Intravesical instillation of liposomal-formulated botulinum toxin A (lipotoxin) has shown therapeutic effects on treatment of refractory overactive bladder without needle injections. We hereby assessed lipotoxin for the treatment of refractory interstitial cystitis/bladder pain syndrome (IC/BPS). METHODS: This two-center, double-blind, randomized, placebo-controlled physician-initiated study enrolled patients with refractory IC/BPS. The patients were assigned to intravesical instillation of lipotoxin (onabotulinumtoxinA 200 U with 80mg sphingomyelin) (n=31), onabotulinumtoxinA 200 U in normal saline (n=28), or normal saline alone (n=31)...
February 12, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28196743/onabotulinumtoxina-in-urinary-incontinence-prospective-study-of-a-case-series
#3
A Martín-Martínez, A Fernández-Mederos, J Á García-Hernández
OBJECTIVE: To assess the safety and efficacy of a single intravesical injection of onabotulinumtoxinA (OnaBTA) for treating urge urinary incontinence (UUI) in women. METHOD: We performed a prospective case-series study of consecutive patients with refractory UUI treated with an intravesical injection of OnaBTA. The patients were administered 100 units of OnaBTA injected into the bladder wall following 4 weeks of flushing with anticholinergic agents or beta 3 agonists...
February 10, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28170477/onabotulinumtoxina-vs-sacral-neuromodulation-for-urgency-incontinence-reply
#4
LETTER
Cindy L Amundsen, Holly E Richter, Dennis Wallace
No abstract text is available yet for this article.
7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28170474/onabotulinumtoxina-vs-sacral-neuromodulation-for-urgency-incontinence
#5
LETTER
John F McCauley, Hector M Gonzalez, David James Osborn
No abstract text is available yet for this article.
7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28170473/onabotulinumtoxina-vs-sacral-neuromodulation-for-urgency-incontinence
#6
LETTER
Bertil F M Blok
No abstract text is available yet for this article.
7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28161352/the-efficacy-and-safety-of-onabotulinumtoxina-or-solifenacin-compared-with-placebo-in-solifenacin-na%C3%A3-ve-patients-with-refractory-overactive-bladder-results-from-a-multicenter-randomized-double-blind-phase-3b-trial
#7
Sender Herschorn, Alfred Kohan, Philip Aliotta, Kurt McCammon, Rajagopalan Sriram, Steven Abrams, Wayne Lam, Karel Everaert
PURPOSE: This double-blind, randomized study compared the efficacy/safety of onabotulinumtoxinA or solifenacin versus placebo in overactive bladder patients with urinary incontinence who had an inadequate response to/were intolerant of an anticholinergic. A post-hoc analysis compared effects of onabotulinumtoxinA versus solifenacin. MATERIALS AND METHODS: Solifenacin-naïve patients were randomized to onabotulinumtoxinA 100U, solifenacin 5mg (could escalate to 10mg at week 6 with predefined criteria), or placebo...
February 1, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28139068/positive-outcomes-with-first-onabotulinumtoxina-treatment-persist-long-term-with-repeat-treatments-in-patients-with-neurogenic-detrusor-overactivity
#8
Pierre Denys, Roger Dmochowski, Philip Aliotta, David Castro-Diaz, Bertil Blok, Karen Ethans, Tamer Aboushwareb, Andrew Magyar, Michael Kennelly
OBJECTIVE: To examine whether response to first treatment with onabotulinumtoxinA is predictive of long-term treatment outcome in neurogenic detrusor overactivity (NDO) patients. PATIENTS AND METHODS: NDO patients in a 3-year extension study (following a 52-week phase 3 study) received onabotulinumtoxinA 'as needed' based on fulfilment of prespecified retreatment criteria. This post-hoc analysis included patients who received only the 200U dose during the phase 3 and extension studies...
January 31, 2017: BJU International
https://www.readbyqxmd.com/read/28118733/safety-and-efficacy-of-letibotulinumtoxina-botulax%C3%A2-in-treatment-of-post-stroke-upper-limb-spasticity-a-randomized-double-blind-multi-center-phase-iii-clinical-trial
#9
Kyung Hee Do, Min Ho Chun, Nam-Jong Paik, Yoon Ghil Park, Shi-Uk Lee, Min-Wook Kim, Don-Kyu Kim
OBJECTIVE: To investigate a new botulinum neurotoxin type A, termed letibotulinumtoxinA(Botulax(®)) and compare its efficacy and safety for post-stroke upper limb spasticity with that of onabotulinumtoxinA(Botox(®)). DESIGN: A prospective, double-blinded, multicenter, randomized controlled clinical study. SETTING: Six university hospitals in Korea. SUBJECTS: A total of 187 stroke participants with upper limb spasticity...
January 1, 2017: Clinical Rehabilitation
https://www.readbyqxmd.com/read/28089729/urinary-biomarkers-in-women-with-refractory-urgency-urinary-incontinence-randomized-to-sacral-neuromodulation-versus-onabotulinumtoxina-compared-to-controls
#10
Holly E Richter, Pamela Moalli, Cindy L Amundsen, Anna P Malykhina, Dennis Wallace, Rebecca Rogers, Deborah Myers, Maria Paraiso, Michael Albo, Haolin Shi, Tracy Nolen, Susie Meikle, R Ann Word
PURPOSE: To measure urinary biomarker levels in women with refractory urgency urinary incontinence (UUI) and controls at baseline and 6 months post treatment from sacral neuromodulation (SNM) or intradetrusor injection onabotulinumtoxinA and to assess association of baseline biomarkers to post treatment UUI episodes (UUIE) and overactive bladder (OAB) symptom bother outcomes. MATERIALS AND METHODS: First morning urines were collected from consented trial participants and age-matched women without UUI...
January 13, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28012773/onabotulinumtoxina-for-the-treatment-of-patients-with-overactive-bladder-and-urinary-incontinence-results-of-a-phase-3-randomized-placebo-controlled-trial
#11
Victor W Nitti, Roger Dmochowski, Sender Herschorn, Peter Sand, Catherine Thompson, Christopher Nardo, Xiaohong Yan, Cornelia Haag-Molkenteller
PURPOSE: Overactive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related quality of life. Oral anticholinergics are the mainstay of pharmacological treatment but they are limited by inadequate efficacy or side effects, leading to a high discontinuation rate. We report the results of the first large (557 patients), phase 3, placebo controlled trial of onabotulinumtoxinA in patients with overactive bladder and urinary incontinence inadequately managed with anticholinergics...
December 21, 2016: Journal of Urology
https://www.readbyqxmd.com/read/28010976/onabotulinumtoxina-for-overactive-bladder-and-urinary-incontinence
#12
Michael B Chancellor
No abstract text is available yet for this article.
December 20, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27973069/real-world-outcomes-and-resource-utilisation-following-onabotulinumtoxina-treatment-for-severe-lower-limb-focal-spasticity-in-adults-database-analysis-at-an-australian-hypertonicity-clinic
#13
M J Frost, C Cave, R Baguley, J Tan
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27969264/efficacy-and-safety-of-onabotulinumtoxin-a-100u-for-treatment-of-urinary-incontinence-due-to-neurogenic-detrusor-overactivity-in-non-catheterising-multiple-sclerosis-patients
#14
P Denys, V Keppenne, A Kohan, B Egerdie, B Brucker, A Magyar, J Nicandro, B Jenkins, E Chartier-Kastler
OBJECTIFS: We evaluated the efficacy/safety of onabotulinumtoxin A 100U versus placebo for treatment of urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO) in non-catheterising multiple sclerosis (MS) patients inadequately managed by≥1 anticholinergic. MéTHODES: A multicentre, double-blind study randomised patients 1:1 to onabotulinumtoxin A 100U (n=66) or placebo (n=78). Assessments (week 6 primary endpoint) included change from baseline in UI episodes (UIE)/day (primary endpoint), maximum cystometric capacity (MCC), maximum detrusor pressure (MDP) during first involuntary detrusor contraction (IDC), incontinence-quality of life (I-QOL) total summary score, and proportions of patients achieving 100% UIE reduction...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27958325/onabotulinumtoxina-urethral-sphincter-injection-as-treatment-for-non-neurogenic-voiding-dysfunction-a-randomized-double-blind-placebo-controlled-study
#15
Yuan-Hong Jiang, Chung-Cheng Wang, Hann-Chorng Kuo
Non-neurogenic voiding dysfunction including dysfunctional voiding and detrusor underactivity caused by a spastic or non-relaxing external urethral sphincter can theoretically be treated by injections of botulinum A toxin into the external urethral sphincter. This randomized, double-blind, placebo-controlled trial was designed to determine the clinical efficacy of onabotulinumtoxinA urethral sphincter injections in patients with dysfunctional voiding or detrusor underactivity. Patients with medically refractory dysfunctional voiding (n = 31) or detrusor underactivity (n = 31) were randomly allocated in a 2:1 ratio to receive either onabotulinumtoxinA (100 U) (n = 38) or placebo (normal saline) (n = 24)...
December 13, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27957623/real-life-data-in-115-chronic-migraine-patients-treated-with-onabotulinumtoxin-a-during-more-than-one-year
#16
I Aicua-Rapun, E Martínez-Velasco, A Rojo, A Hernando, M Ruiz, A Carreres, E Porqueres, S Herrero, F Iglesias, A L Guerrero
BACKGROUND: OnabotulinumtoxinA (OnabotA) is effective in Chronic Migraine (CM) during first year of treatment and longer. In real clinical setting, CM patients with acute Medication Overuse (MO) or concurrently receiving oral preventatives are treated with OnabotA. We aim to assess evolution of CM patients beyond first year on OnabotA. METHODS: Data were retrospectively collected in three headache units. We analyzed cases who had received at least five sessions of OnabotA according to PREEMPT protocol...
December 2016: Journal of Headache and Pain
https://www.readbyqxmd.com/read/27910097/chronic-migraine-an-update-on-physiology-imaging-and-the-mechanism-of-action-of-two-available-pharmacologic-therapies
#17
Sheena K Aurora, Mitchell F Brin
Several lines of research support the hypothesis that migraine is a spectrum of illness, with clinical symptoms that vary along a continuum from episodic migraine to chronic migraine. Physiologic changes may result in episodic migraine evolving into chronic migraine over months to years in susceptible individuals. With chronification, headache frequency increases, becoming more disabling and less responsive to therapy. Neurophysiologic and functional imaging research has reported that chronic migraine may be associated with severity-specific metabolic, functional, and structural abnormalities in the brainstem...
January 2017: Headache
https://www.readbyqxmd.com/read/27908491/clinical-outcomes-of-botox-injections-for-chronic-temporomandibular-disorders-do-we-understand-how-botox-works-on-muscle-pain-and-the-brain
#18
S T Connelly, J Myung, R Gupta, G M Tartaglia, A Gizdulich, J Yang, R Silva
The main objective of this retrospective review was to analyze the clinical outcomes following the use of botulinum toxin (onabotulinumtoxinA, Botox) injections to relieve the symptoms of chronic temporomandibular disorders (TMD). Seventy-one patients with a diagnosis of TMD (according to the RDC/TMD international consortium) associated with or without bruxism and refractory to conventional treatment (e.g. oral appliances, physiotherapy, etc.) received Botox injections into the temporalis and masseter muscles...
March 2017: International Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/27893541/treatment-of-palmar-hyperhidrosis-with-needle-injection-versus-low-pressure-needle-free-jet-injection-of-onabotulinumtoxina-an-open-label-prospective-study
#19
Sophie Vadeboncoeur, Vincent Richer, Mélissa Nantel-Battista, Antranik Benohanian
BACKGROUND: OnabotulinumtoxinA (OnabotA) injections are effective to treat palmar hyperhidrosis (HH) but are quite painful. OBJECTIVE: To evaluate efficacy and pain of OnabotA injection using a needle-free jet apparatus compared with the traditional needle injection to treat palmar HH. METHODS: Twenty patients were recruited for a prospective open-label study. Their right hand was injected with 1% lidocaine with a jet injector, after which OnabotA was injected with a needle...
February 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27889830/urinary-retention-in-female-oab-after-intravesical-botox-injection-who-is-really-at-risk
#20
Pawel Miotla, Rufus Cartwright, Katarzyna Skorupska, Michal Bogusiewicz, Ewa Markut-Miotla, Konrad Futyma, Tomasz Rechberger
INTRODUCTION AND HYPOTHESIS: Intravesical onabotulinumtoxinA (Botox) injections are effective for the treatment of idiopathic overactive bladder (OAB) symptoms. The aim of our study was to assess the predisposing factors for urinary retention in women with OAB after intravesical Botox injection. METHODS: All participants were women of European descent with idiopathic OAB. OnabotulinumtoxinA (100 U) was administered in 20 intra-detrusor injections. Analysis was performed based on the results of safety assessments made during follow-up (FU) visits on weeks 2, 4 and 12, in 208 women who were treated with Botox injections for refractory OAB and who completed all FU visits...
November 26, 2016: International Urogynecology Journal
keyword
keyword
3072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"